Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma

Oncology Reports

Volumn 27, Issue 2, 2012, Pages 333-338

  Abe, Yoshiyuki ^a   Tamura, Katsumi ^a   Sakata, Ikuko ^a   Ishida, Jiro ^a   Ozeki, Yuichi ^b   Tamura, Atsuhisa ^c   Uematsu, Kazutsugu ^d   Sakai, Hiroshi ^e   Goya, Tomoyuki ^f   Kanazawa, Minoru ^g   Machida, Kikuo ^a  

^a Tokorozawa PET Diagnostic Imaging Clinic   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c TOKYO NATIONAL HOSPITAL   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e SAITAMA CANCER CENTER   (Japan)

^f KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

18F fluorodeoxyglucose positron emission tomography computed tomography fusion imaging; Malignant pleural mesothelioma; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DELAYED DIAGNOSIS; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DRUG UPTAKE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PLEURA CANCER; PLEURA MESOTHELIOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; MESOTHELIOMA; MIDDLE AGED; MORTALITY; PLEURA TUMOR; SCINTISCANNING; SURVIVAL;

AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84855218825     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1520     Document Type: Article

References (27)

1. Kramer H, Pieterman RM, Slebos DJ, Timens W, Vaalburg W, Koëter GH and Groen HJ: PET for the evaluation of pleural thickening observed on CT. J Nucl Med 45: 995-998, 2004. (Pubitemid 47611687)
2. Flores RM, Akhurst T, Gonen M, Larson SM and Rusch VW: Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 126: 11-16, 2003. (Pubitemid 36909936)
3. Schaffler GJ, Wolf G, Schoellnast H, Groell R, Maier A, Smolle-Jüttner FM, Woltsche M, Fasching G, Nicoletti R and Aigner RM: Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 231: 858-865, 2004. (Pubitemid 38668109)
4. Ueda S, Tsuda H, Asakawa H, Shigekawa T, Fukatsu K, Kondo N, Yamamoto M, Hama Y, Tamura K, Ishida J, Abe Y and Mochizuki H: Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 38: 250-258, 2008. (Pubitemid 351583988)
5. Weiler-Sagie M, Bushelev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Barak A, Ben-Arie Y, Bar-Shalom R and Israel O: (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 51: 25-30, 2010.
6. 18F-FDG positron emission tomography/computed tomography for diagnosis of pyothorax-associated lymphoma: A report of three cases. Oncol Lett 1: 833-836, 2010.
7. Orki A, Akin O, Tasci AE, Ciftci H, Urek S, Falay O and Kutlu CA: The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg 57: 217-221, 2009.
8. Mak V, Davies E, Putcha V, Choodari-Oskooei B and Møller H: The epidemiology and treatment of mesothelioma in South East England 1985-2002. Thorax 63: 160-166, 2008. (Pubitemid 351236484)
9. Takeshima Y, Inai K, Amatya VJ, Gemba K, Aoe K, Fujimoto N, Kato K and Kishimoto T: Accuracy of pathological diagnosis of mesothelioma cases in Japan: clinicopathological analysis of 382 cases. Lung Cancer 66: 191-197, 2009.
10. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M and Stahel RA: Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22: 3451-3457, 2004. (Pubitemid 41103650)
11. Flores RM: The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 49 (Suppl 1): 27-32, 2005.
12. Tan C, Barrington S, Rankin S, Landau D, Pilling J, Spicer J, Cane P and Lang-Lazdunski L: Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. J Thorac Oncol 5: 385-388, 2010.
13. Flores RM, Akhurst T, Gonen M, Zakowski M, Dycoco J, Larson SM and Rusch VW: Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 132: 763-768, 2006. (Pubitemid 44415880)
14. Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, Musk AW, McCoy MJ, Segal A, Robins P and Byrne MJ: A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 16: 2409-2417, 2010.
15. Gerbaudo VH, Mamede M, Trotman-Dickenson B, Hatabu H and Sugarbaker DJ: FDG PET/CT patterns of treatment failure of malignant pleural mesothelioma: relationship to histologic type, treatment algorithm, and survival. Eur J Nucl Med Mol Imaging 38: 810-821, 2011.
16. 18F-FDG positron emission tomography/computed tomography (PET/CT) in primary pancreatic lymphoma: A case report. Oncol Lett 1: 605-607, 2010.
17. Ozeki Y, Abe Y, Kita H, Tamura K, Sakata I, Ishida J and Machida K: A case of primary lung cancer lesion demonstrated by F-18 FDG positron emission tomography/computed tomography (PET/CT) one year after the detection of metastatic brain tumor. Oncol Lett 2: 621-623, 2011.
18. Travis WD, Brambilla E, Muller-Hermelink HK, et al: World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press, Lyon, pp125-136, 2004.
19. Yamamoto Y, Kameyama R, Togami T, Kimura N, Ishikawa S, Yamamoto Y and Nishiyama Y: Dual time point FDG PET for evaluation of malignant pleural mesothelioma. Nucl Med Commun 30: 25-29, 2009.
20. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, Flores R, Friedberg JS, Pisters K, Monberg M, Obasaju CK and Vogelzang NJ: Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27: 3007-3013. 2009.
21. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003. (Pubitemid 46606305)
22. Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, Ahn MJ, Kim TS, Yi CA and Chung MJ: Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 17: 2787-2794, 2010.
23. Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B and Stahel RA: Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 67: 311-317, 2010.
24. Edwards JG, Abrams KR, Leverment JN, Spyt TJ, Waller DA and O'Byrne KJ: Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55: 731-735, 2000. (Pubitemid 30660898)
25. Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J and Rudd R: Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23: 184-189, 2005. (Pubitemid 41702637)
26. Otsuka H, Terazawa K, Morita N, Otomi Y, Yamashita K and Nishitani H: Is FDG-PET/CT useful for managing malignant pleural mesothelioma? J Med Invest 56: 16-20, 2009.
27. Sørensen JB, Ravn J, Loft A, Brenøe J and Berthelsen AK; Nordic Mesothelioma Group: Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumo nectomy. Eur J Cardiothorac Surg 34: 1090-1096, 2008.